昆明山海棠联合复方松馏油糊治疗慢性湿疹疗效观察

目的评价昆明山海棠联合复方松馏油糊治疗慢性湿疹的疗效。方法治疗组予昆明山海棠2片,3次/d口服,同时每日外用复方松馏油糊封包;对照组仅用复方松馏油糊封包。两组患者的疗程均为5周,分别于治疗第1周、3周和5周末观察疗效。结果治疗1周、3周和5周时,治疗组有效率分别为66.67%,73.33%和96.67%,对照组分别为28.57%,39.29%和71.43%,差异均有统计学意义(P均<0.05)。治疗组和对照组均出现了不良反应,但未影响治疗。结论昆明山海棠联合复方松馏油糊治疗慢性湿疹疗效好,不良反应少,值得临床应用。     

温泉浴联合复方松馏油糊治疗慢性湿疹的疗效观察

目的探讨温泉浴联合复方松馏油糊治疗慢性湿疹的疗效和安全性。方法治疗组和对照组均口服氯雷他啶片10mg,1次/早,赛庚啶片2mg,1次/晚,同时外用松馏油糊局部封包患处,1次/d;此外治疗组联合给予温泉浴1次/d。1周、2周及4周末比较两组疗效及安全性。结果治疗组和对照组在治疗1周、2周、4周末的有效率分别为38.24%,76.47%,94.12%和32.35%,41.18%,64.71%。1周末两组有效率比较差异无统计学意义(P>0.05);2周、4周末有效率比较差异有统计学意义(P<0.05)。疗程中均无不良反应。结论温泉浴联合复方松馏油糊治疗慢性湿疹安全、疗效显著。     

加味启脾丸颗粒治疗儿童特应性皮炎疗效观察

目的观察加味启脾丸颗粒治疗儿童特应性皮炎疗效。方法治疗组27例予加味启脾丸颗粒治疗,对照组24例予赛庚啶治疗。结果治疗组有效率为62.96%,对照组为29.17%,两组有效率比较差异有显著性(P<0.05)。结论加味启脾丸颗粒冲服治疗儿童特应性皮炎有一定的疗效。     

三联疗法治疗寻常性银屑病疗效观察

目的　观察中药药浴联合窄谱中波紫外线(NB-UVB)照射、复方松馏油封包治疗寻常性银屑病的临床疗效。方法　将入选的575例寻常性银屑病患者按门诊及住院顺序编号,采用随机数字表法分成3组。对照1组以NB-UVB全身照射联合复方松馏油封包治疗;对照2组以中药煎液沐浴联合复方松馏油封包治疗;治疗组为中药药浴联合NB-UVB照射、复方松馏油封包治疗,方法同前两组。3组均以2周为1个疗程, 2个疗程后判定疗效。 结果 治疗组有效率为96.89% ,对照1组为83.16% ,对照2组为86.45%,治疗组疗效优于对照组1组和2组,差异均有统计学意义(P<0.05)。治疗组复发率明显低于对照1组,差异有统计学意义(P<0.05)。结论　中药药浴联合NB-UVB照射加复方松馏油封包治疗寻常性银屑病疗效较好,可缩短疗程,降低复发率及不良反应。     

卤米松乳膏治疗儿童特应性皮炎疗效观察

目的　观察卤米松乳膏治疗儿童特应性皮炎的临床疗效及安全性。方法　用0. 05%的卤米松乳膏外涂皮损并与0. 025%的丙酸倍氯米松乳膏比较,头面部皮损分别将此两种乳膏与红霉素软膏等体积混合外涂,疗程7天。结果　观察组治愈率为57. 89%,有效率为73. 68%;对照组治愈率为36. 84%,有效率为52. 63%。两组比较差异有显著性(P<0. 05)。结论　卤米松乳膏治疗儿童特应性皮炎起效快,疗效肯定,耐受性好。     

白芍总苷治疗寻常性银屑病的临床疗效观察

目的:观察白芍总苷治疗寻常性银屑病的疗效及不良反应.方法:采用随机对照临床试验.90例符合纳入标准的患者随机分为3组.治疗组30例及对照组60例,分别使用白芍总苷1.8 g/d加5%松馏油软膏(A组)、5%松馏油软膏加海棠合剂(B组)及单用5%松馏油软膏(C组).疗程均为6周.治疗前、后检查3组患者的血、尿、粪常规及肝、肾功能,同时观察患者的不良反应.结果:A组有效率为83.3%,B组及C组分别为86.7%、46.7%.A组和B组有效率差异无统计学意义(P > 0.05);而A、B组分别与C组比较有效率差异均有统计学意义(P < 0.05).3组的不良反应均较少.结论:白芍总苷联合5%松馏油软膏治疗寻常性银屑病疗效明显,且不良反应少,安全性高.     

淀粉浴联合艾洛松及西替利嗪治疗儿童特应性皮炎的疗效观察

目的：评价淀粉浴联合艾洛松及西替利嗪治疗儿童特应性皮炎的临床疗效。方法：67例患儿分为两组,实验组35例,对照组32例。两组均口服西替利嗪,实验组予淀粉浸浴,每天1次,每次20分钟,外搽艾洛松,每天1次;对照组外搽艾洛松,每天1次,连续2周。结果：实验组有效率为91．43％,对照组有效率为71．88％,两组有效率有统计学意义（P〈0．05）。实验组不良反应轻微。结论：淀粉浴联合艾洛松及西替利嗪治疗儿童特应性皮炎疗效好。     

矿泉浴联合5%松馏油软膏治疗银屑病的疗效观察

目的观察矿泉浴联合5%松馏油软膏封包治疗寻常性银屑病的疗效和安全性。方法将150例寻常性银屑病患者分为两组,均采用5%松馏油软膏封包治疗,1次/d,治疗组同时采用矿泉浴治疗,1次/d,30min/次,两组疗程均为6周。在治疗后3,6周根据PASI评估疗效。结果治疗3周时,治疗组PASI评分下降值显著高于对照组(P<0.01)。疗程结束时,治疗组有效率为91.00%,对照组有效率为70.00%,两组比较差异有显著性(P<0.01)。治疗组和对照组的不良反应发生率分别为15.00%和26.00%,两组差异无显著性(P>0.05)。两组疗法都未出现系统不良反应。结论矿泉浴联合5%松馏油软膏封包治疗寻常性银屑病疗效好,能迅速缓解病情,是一种安全有效的治疗方法。     

复方甘草甜素片联合仙特明治疗面部激素依赖性皮炎疗效观察

目的观察复方甘草甜素治疗激素依赖性皮炎的疗效和安全性。方法对照组口服仙特明片10 mg,1次/d,同时予氧化锌软膏外用。治疗组在对照组基础上加用复方甘草甜素片50 mg口服,3次/d,疗程均为21天。结果治疗组45例患者中有43例可评价疗效,有效率86.0%;对照组45例中有41例可评价疗效,有效率56.1%,两组疗效比较差异有显著性(P<0.01)。结论复方甘草甜素联合仙特明治疗激素依赖性皮炎安全有效。     

复方紫草油联合氯雷他定治疗轻、中度特应性皮炎的临床观察

目的观察复方紫草油联合氯雷他定治疗轻、中度特应性皮炎的临床效果。方法选择2018年6月1日至2019年6月31日我院皮肤科门诊收治的61例轻、中度特应性皮炎(AD)患者作为研究对象,以给予复方紫草油联合氯雷他定治疗为观察组31例;以给予氯雷他定治疗为对照组30例。对比两组研究对象同疗程内的治疗效果及特应性皮炎评估SCORAD、皮肤病生活质量DLQI各指标变化。结果观察组治疗有效率(93.55%)明显高于对照组(66.67%);观察组的SCORAD和DLQI评估分值均低于对照组,经比较组间差异具有可比性(P 0.05)。结论复方紫草油联合氯雷他定治疗轻、中度特应性皮炎的临床效果显著,皮损及瘙痒状况改善明显、可提高患者的生活质量。     

他克莫司软膏治疗光敏性皮肤病临床观察

目的探讨0.1%他克莫司软膏治疗成人光敏性皮肤病的疗效和安全性。方法入选的30例光敏性皮肤病患者均口服昆明山海棠片,皮损一侧外涂他克莫司软膏(试验侧),另一侧外涂复方氧化锌软膏治疗(对照侧),分别于治疗前和治疗后第1,2和4周时各随访1次,评价两组的疗效和安全性。结果治疗结束时,试验侧有效率为93.33%,显著高于对照侧(86.67%),差异有统计学意义(P<0.001),且试验侧皮肤的水分和油脂改善程度及患者的满意度明显优于对照侧,差异有统计学意义(P均<0.05),但弹性无明显改变,差异无统计学意义(P>0.05)。试验侧不良反应(瘙痒、灼痛等)有9例,对照侧不良反应(红斑、瘙痒等)有1例。结论 0.1%他克莫司软膏治疗成人光敏性皮肤病具有良好的疗效和安全性。     

Spotlight on topical pimecrolimus in atopic dermatitis

Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a nonsteroid, has anti-inflammatory activity, and has demonstrated efficacy in reducing symptoms of atopic dermatitis in adult and pediatric patients when applied topically. Compared with vehicle, topical pimecrolimus 1.0% cream was significantly more effective at reducing symptoms of atopic dermatitis, as measured by the Eczema Area and Severity Index (EASI), in infants aged 3 to 23 months, children aged 2 to 17 years, and adults. The median reductions from baseline in the total EASI score in adults after treatment with pimecrolimus 1.0% or corresponding vehicle twice daily for 3 weeks were 47 and 0%, respectively. In infants and children, treatment with pimecrolimus 1.0% twice daily for 6 weeks resulted in significant decreases in mean EASI scores compared with vehicle. The severity of pruritus was significantly reduced in patients of all age groups after topical treatment with pimecrolimus 1.0% cream. Compared with vehicle, the incidence of eczematous flares was also reduced by intermittent long-term use of topical pimecrolimus 1.0% in adults, children and infants. Sixty-one percent of children treated with pimecrolimus for 1 year completed the first 6 months of treatment without experiencing a flare, compared with 35% of patients who received vehicle. Furthermore, the use of topical corticosteroids for the treatment of uncontrolled flares in adults, children and infants was lower in the pimecrolimus groups than in the vehicle groups. Topical pimecrolimus 1.0% cream is well tolerated in atopic dermatitis patients of all age groups. There were no clinically relevant systemic adverse events reported from any of the studies in patients with atopic dermatitis. The most frequently reported adverse events pertained to application site reactions, such as burning and a feeling of warmth. In conclusion, topical pimecrolimus 1.0% cream has shown efficacy in the treatment of mild to moderate atopic dermatitis in infants, children and adults. Although tolerability data concerning infants and children have not yet been published in full, the drug appears to be well tolerated in all age groups, and there have been no reports of clinically relevant systemic adverse events. Furthermore, pimecrolimus has shown no potential for skin atrophy, a problem commonly associated with treatment with topical corticosteroids. Topical pimecrolimus 1.0% provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis.     

夫西地酸乳膏治疗儿童脓疱疮疗效观察

目的观察夫西地酸乳膏治疗儿童脓疱疮的疗效和安全性。方法将2007年6月～2008年6月就诊的100例脓疱疮患儿分为2组,治疗组50例,外搽2%夫西地酸乳膏3次/d,对照组50例,外搽2%莫匹罗星软膏3次/d,疗程均为7天。结果治疗组有效率为94.00%,对照组为92.00%,两组有效率比较,差异无显著性意义(P>0.05),治疗期间均未出现不良反应。结论2%夫西地酸乳膏治疗儿童脓疱疮有效,安全性高。     

他克莫司软膏治疗儿童特应性皮炎疗效和依从性评价

目的评价0.03%他克莫司软膏治疗儿童轻、中度特应性皮炎(AD)的疗效和安全性及依从性。方法采用随机双盲平行对照方法将入选的60例AD患儿分为对照组和试验组,每组各30例。试验组患儿外用0.03%他克莫司软膏,对照组患儿外用凡士林乳膏、夫西地酸软膏,两组均连续治疗3周,采用AD评分评价疗效。结果试验组患儿瘙痒、症状积分下降明显大于对照组(P<0.05);症状控制时间和临床治愈用药时间明显短于对照组(P<0.05)。试验组和对照组治疗的有效率分别为93.3%和69.5%,两组疗效比较差异有统计学意义(P<0.05);试验组和对照组依从率分别为100%和76.7%,两组比较差异具有统计学意义(P<0.05)。结论 0.03%他克莫司软膏治疗儿童轻、中度AD安全而有效,患儿依从性良好。     

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

Tacrolimus ointment is a topical calcineurin inhibitor for the treatment of atopic dermatitis. The primary objective of this open-label study was to assess the long-term safety of tacrolimus ointment. The primary end-point was the incidence of adverse events. Secondary end-points included the Eczema Area and Severity Index and a modified version of this index. A total of 466 children with atopic dermatitis, aged 2-15 years, applied 0.03% or 0.1% tacrolimus ointment twice daily for up to 29.5 months. Skin burning and pruritus were the most common application site events; their prevalence decreased over time. There was no increase in viral infections or other adverse events over time. Laboratory profiles were consistent with those reported in atopic populations. Substantial improvement in all efficacy end-points was observed by week 2 and maintained throughout the study. Long-term treatment with tacrolimus ointment is safe and effective in these patients with atopic dermatitis.     

外用丁酸氢化可的松乳膏联合一种皮肤膏剂敷料治疗特应性皮炎的随机开放对照研究

目的:评价外用丁酸氢化可的松乳膏联合一种皮肤膏剂敷料治疗轻中度特应性皮炎（AD）的疗效和安全性。方法:2019年7月至2020年6月,于首都医科大学附属北京友谊医院入组60例轻中度AD患者,采用随机数字表法分为两组,试验组先搽一种皮肤膏剂敷料（商品名芙汭膏剂）后涂丁酸氢化可的松乳膏,对照组先搽上述皮肤膏剂敷料的基质,后...     

Pimecrolimus

Pimecrolimus (Elidel) is a topically active, nonsteroid, calcineurin inhibitor that has shown efficacy in controlling symptoms of atopic dermatitis in adult and pediatric patients. Topical pimecrolimus 1% cream is approved in the US for the short-term and intermittent long-term treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients aged >/=2 years who do not respond well to, or may have adverse effects with, conventional treatments. Pimecrolimus 1% cream is an effective and well tolerated treatment for atopic dermatitis in infants, children, adolescents, and adults. Pimecrolimus is effective at reducing the incidence of disease flares and, thus, the need for rescue treatment with topical corticosteroids. The drug also improves the health-related quality of life (HR-QOL) of children and adolescents, and improves the QOL of parents of children with atopic dermatitis. Furthermore, pimecrolimus does not cause skin atrophy, a problem commonly associated with topical corticosteroids, and is not associated with clinically relevant systemic adverse events. Thus, topical pimecrolimus 1% cream is an effective treatment option for the management of mild-to-moderate atopic dermatitis.     

【开放获取】复方紫草油改善轻中度尿布皮炎临床症状的多中心、开放、随机对照临床研究

【摘要】 目的 评价外用复方紫草油治疗轻中度尿布皮炎的临床疗效和安全性。方法 2019年7月至2020年8月采用多中心、随机、阳性药平行对照的研究方法，在全国19家医院纳入0 ~ 12月龄轻中度尿布皮炎患儿，按随机数字表法分为试验组和对照组。试验组外用复方紫草油，对照组外用氧化锌乳膏，每日6 ~ 8次，观察期为7 d。分别于治疗第0、7天进行访视，评估总有效率、临床治愈时间，比较两组治疗前后皮肤病家庭生活质量评分（DFI）的变化，记录不良事件发生情况。两组间正态分布的连续性资料比较采用成组t检验，非正态分布的连续性资料比较采用Wilcoxon秩和检验；组间无序分类资料比较采用χ2检验/Fisher确切概率法。对生存资料绘制生存曲线，两组间比较采用Log-Rank检验。结果 343例尿布皮炎患儿中，31例违背方案，312例纳入符合方案分析集（试验组157例、对照组155例），均完成第0、7天访视。试验组总有效率87.26%（137/157），对照组总有效率78.71%（122/155），两组间比较差异有统计学意义（χ2 = 4.04，P = 0.044）。试验组和对照组中位临床治愈时间分别为5.33 d、6.13 d，差异有统计学意义（χ2 = 4.67，P = 0.025）。治疗7 d后，两组DFI均较治疗前下降，但两组间DFI差异无统计学意义（试验组4.02 ± 6.96，对照组3.58 ± 5.90，Z = -0.39，P = 0.686）。试验组不良事件发生率为2.92%（5/171），对照组5.45%（9/165），两组间差异无统计学意义（χ2 = 0.03，P = 0.865）。结论 复方紫草油可显著改善尿布皮炎患儿临床严重程度，提高总有效率，缩短临床治疗时间，提高患儿家庭生活质量，且安全性好。     

除湿止痒软膏治疗轻度婴儿期特应性皮炎的有效性及安全性多中心临床研究

目的 评价除湿止痒软膏治疗轻度婴儿期特应性皮炎的有效性和安全性.方法 采用随机、开放、阳性药物平行对照的多中心研究方法,共入组婴儿期特应性皮炎患儿204例,其中试验组103例外用除湿止痒软膏,阳性对照组101例外用丁酸氢化可的松乳膏,评估治疗前及治疗第7天和14天患儿湿疹面积及严重度指数(EASI)改善情况、患儿生活质量改善情况及不良事件和不良反应的发生情况.结果 全分析集分析结果显示,两组患儿经治疗后疾病严重程度均明显缓解.试验组98例,基线、7d和14 d时EASI值分别为2.47±4.04、0.92±1.25、0.39±1.04,7d和14 d分别与基线值比较,经配对秩检验,T值分别为-1 666和-1 793,均P＜0.001,差异有统计学意义;对照组101例,基线、7d和14 d时EASI值分别为2.13±2.01、0.85±1.58、0.45±1.65,7d和14d分别与基线比较,T值分别为-1 951和-1 941,均P＜0.001,差异有统计学意义;试验组与对照组间治疗前、治疗第7天和第14天比较,差异均无统计学意义.7d随访时,试验组有效率为47.96％(47例),对照组为55.44％(56例);治疗第14天,试验组为79.59％(78例),对照组为84.16％(85例),经独立样本秩和检验,均P＞ 0.05,差异无统计学意义.试验组不良事件发生率为2.90％(3例),以红斑瘙痒、脱屑为主;对照组发生率为6.90％(7例),以色素减退、毛细血管扩张、脱屑、色素沉着为主,两组差异无统计学意义(P＞0.05).结论 除湿止痒软膏治疗轻度婴儿期特应性皮炎疗效确切,安全性、耐受性好,可为轻度婴儿期特应性皮炎的治疗选择方案之一.     

他克莫司软膏治疗儿童特应性皮炎的临床研究

目的　评价他克莫司软膏治疗儿童特应性皮炎 (AD)的疗效与安全性。方法　采用随机、双盲、赋形剂对照临床研究方法,将 36例儿童AD患者随机分为两组,按 1∶1比例分别接受 0. 03%他克莫司软膏或赋形剂治疗,观察治疗第 1, 2和 3周的临床疗效和不良反应。结果　0. 03%他克莫司软膏组有效率为 83. 3% (15 /18),明显高于赋形剂组的 27. 8% (5 /18),差异非常显著(P<0. 001);总体疗效比较,他克莫司软膏组亦优于赋形剂组 (P=0. 002);治疗后第 1,2, 3周患者的主要症状 /体征指标平均值均明显低于赋形剂组,组间差异显著(P<0.01~P<0. 05),治疗后患者的生活质量亦明显改善。药物相关不良反应主要表现为一过性局部刺激,组间比较差异无显著性 (P>0. 05)。两组患者均未出现严重不良反应。结论　0. 03%他克莫司软膏治疗儿童特应性皮炎安全有效。